AustriaThe United States has approved the first flu vaccine based on mRNA technology, developed by Moderna. The Food and Drug Administration (FDA) granted standard approval for adults aged 50 to 64 and accelerated approval for those over 65. While the vaccine is already available for older adults, Moderna must conduct additional studies to confirm its effectiveness in this age group. The vaccine uses messenger RNA to instruct cells to produce a viral protein, triggering an immune response similar to traditional vaccines. Clinical trials involving nearly 41,000 people showed the mRNA vaccine was 26.6% more effective than conventional flu vaccines in the 50–64 age group. It also generated stronger antibody responses in individuals over 65 compared to high-dose traditional vaccines. Researchers highlight the advantage of mRNA vaccines being faster to manufacture, allowing quicker adaptation to virus mutations. The World Health Organization typically recommends which virus strains should be included in seasonal flu vaccines for each hemisphere, usually in February for the northern hemisphere and September for the southern hemisphere. Common side effects reported include fatigue and headaches.
Bias read (Center): The article provides factual information about the approval of an mRNA-based flu vaccine, focusing on clinical data, manufacturing advantages, and health outcomes. There is no evident ideological framing, biased language, or selective sourcing that would indicate a political lean. The content is non
